Humira LOE Is ‘Uncharted Territory’ As Fierce Competition Expected

Q&A With AmerisourceBergen’s Biosimilar Commercialization Director Brian Biehn

Discussing the latest developments in the US biosimilars market, AmerisourceBergen’s senior director of biosimilar commercialization, Brian Biehn, talks about what we can expect from competition to Humira in 2023, how the first ophthalmology biosimilars are faring, and potential changes on the horizon at the FDA that could smooth the path to market for biosimilars sponsors.

Empty map uncharted territory
Humira is “uncharted territory” for US biosimilars • Source: Shutterstock

As senior director of biosimilar commercialization at AmerisourceBergen, Brian Biehn focuses on successfully executing commercialization opportunities for AmerisourceBergen while providing customers with choice, access, and savings.

And as the biosimilars market continues to expand in the US, Biehn partners with manufacturers in the pre-commercial, launch, and post-launch phases to

More from Biosimilars

More from Products

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By 

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By 

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By 

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.